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Background: The high cost and prolonged timeline of new drug discovery and development are major roadblocks
to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most
common cause of fatal fungal infections in humans and costs $2–4 billion dollars to treat in the US alone.
Methods: To accelerate drug discovery, we screened a library of 1581 existing FDA approved drugs, as well as drugs
approved abroad, for inhibitors of C. albicans. The screen was done on YPD yeast growth media as well as on the
serum plate assay developed in this study.
Results: We discovered that fifteen drugs, all which were originally approved for treating various infectious and non-
infectious diseases, were able to kill Candida albicans. Additionally, one of those drugs, Octodrine, displays wide-
spectrum anti-microbial activity. Compared to other selected anti-Candida drugs, Octodrine was shown to be one of
the most effective drugs in killing serum-grown Candida albicans without significantly affecting the survival of host
macrophages and skin cells.
Conclusions: This approach is useful for the discovery of economically viable new therapies against infectious diseases.
Keywords: Antifungal, Drug-discovery, Off-label drug use, Small moleculesBackground
While almost all of us possess Candida albicans in our oral
cavity, gastrointestinal tracts, genitourinary tracts, and on
skin as a relatively harmless commensal organism, C. albi-
cans is a major systemic fungal pathogen in humans [1].
Candida evades and escapes from the host’s innate immun-
ity, causing irritating and recurrent infections that can range
from thrush in immunocompetent colonized hosts, to life-
threatening systemic infections in immunocompromised in-
dividuals such as patients with HIV, or those receiving
immunesuppressing cancer chemotherapy and corticoste-
roids. Surprisingly, only 10 to 20% of individuals who
develop bloodstream Candida infections are seriously im-
munocompromised. A large majority of patients develop
Candida infections because they have become more suscep-
tible while hospitalized due to the use of broad-spectrum
antibiotics, surgery, and intravenous catheters. As a result,
infections from C. albicans ranks as the fourth most* Correspondence: mikhail_martchenko@kgi.edu
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The cost of treating bloodstream Candida infections is $2–
4 billion per year in the US alone [2]. In the US, annual inci-
dence of systemic candidiasis is approximately 70,000 cases
per year, which results in the death rate of about 30 to 40%,
even after treatment with antifungal therapy [3].
The situation is especially grave in cancer patients. The
incidence of Candida infection in all cancer patients is
very high, ranging from 40 to 88 % [4, 5]. The mortality
rate among the Candida infected cancer patients reaches
an alarmingly high 75 % amongst the Filipino and Pacific
Islanders [5]. Early antifungal treatment, although poorly
tolerated by the host, is mandatory to improve the survival
of cancer patients. Unfortunately, 30 % of Candida isolates
are resistant to all antifungal treatments [6].
Host serum plays a prominent role in the pathogenicity of
C. albicans. On the one hand, serum promotes morpho-
logical switching of Candida from yeast to hyphal forms,
which is necessary for its evasion of phagocytosis and organ
colonization [7]. On the other hand, serum is known tole distributed under the terms of the Creative Commons Attribution License
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gether, these laboratory observations explain in part the clin-
ical mortality observed during Candida blood infections,
even when patients are treated with antifungals [5].
Several clinical and laboratory data suggests that cur-
rently available antifungal therapies are mostly ineffective in
treating Candida infections [9]. Despite extensive research
dedicated to the development of new therapeutic strategies,
there are only a limited number of available drugs to fight
against invasive fungal infections. Indeed, only four molecu-
lar classes targeting three distinct fungal metabolic path-
ways are currently used in clinical practice to treat systemic
fungal infections. These include: fluoropyrimidine analogs,
polyenes, azoles, and echinocandins [9, 10]. However, the
efficacy of some of these drugs is severely limited because
of their unacceptable toxicity, poor activity in blood, or the
emergence of resistance; thereby underscoring an urgent
necessity for new antifungal agents. Several other classes,
such as morpholines and allylamines are only used as top-
ical agents due to either their poor efficacy, or severe ad-
verse effects when administered systemically [9, 10].
Unfortunately, the development of an entirely new drug
is a long and expensive process. New drugs have to
undergo an arduous approval process by the FDA in order
to establish safety of the drug for human consumption
[11]. We propose that the repurposing of existing FDA-
approved drugs as antifungal agents may decrease the
time and effort of bringing drugs with novel antifungal
activity from the bench to the bedside. Recently, another
group investigated the ability of FDA-approved drugs to
inhibit C. albicans biofilm formation by screening the
Prestwick Library, a commercially available chemical
library of 1200 drugs [12]. However, C. albicans biofilm
formation is just one of many pathogenesis strategies, such
as yeast-to-hyphal phenotypic switching, white-opaque
phenotypic switching, ability to adhere to mammalian
tissues, and secretion of aspartyl proteinases [1, 7]. The
goal of this study is to identify drugs capable of killing
blood-borne Candida albicans, and we use serum as an
in vitro surrogate of host blood. To this end, we have
tested the anti-Candida activity of drugs from the Johns
Hopkins Clinical Compound Library (JHCCL) [13] on
Candida grown on serum-containing media. This library
consists of drug-compounds that are FDA-approved with a
diverse range of functions, mechanisms of action and well-
characterized pharmacological and toxicological properties.
Methods
Candida albicans and bacterial strains
Strain SN250 is the wild type reference strain of C. albi-
cans. It serves as the reference strain for our genetic
knockout library screen. It is derived from the wild type
strain SC5314, a human clinical isolate recovered from a
patient with generalized candidiasis [14]. SN250 wasused for drug screening experiments. The bacterial strains
consisted of Bacillus cereus strain 10987 and Escherichia
coli strain C600. The genetic screen for mutant sensitivity
to Octodrine was tested with three C. albicans libraries
that were previously created in [15–17].
Media and growth conditions
C. albicans strains were cultured in liquid YPD medium
at 30 °C overnight. E. coli and B. cereus were cultured in
liquid LB medium at 37 °C and 30 °C, respectively,
shaking overnight. A novel method to incorporate fetal
bovine serum to agar was devised. Fetal bovine serum
was preheated in a water bath set at 65 °C. We found
that isothermal conditions of the two mixtures elimi-
nated the formation of foam upon coalescence. The agar
solution for the serum mixture consisted of 16 g agar,
which was then brought up to 300 ml with nanopure
water. The agar solution was then autoclaved at 120 °C
for 45 min. The agar and serum mixtures were then
amalgamated while in their isothermal states.
Chemicals
An FDA-approved drug library comprising of 1500 drugs
was purchased from Johns Hopkins, titled, Johns Hopkins
Clinical Compound Library (JHCCL) version 1.0. The
drugs arrived as 10 mM stock solutions in sealed microti-
ter plates and were made using DMSO or water as sol-
vents. Drugs were arrayed in 96-well plates and screened
at a stock concentration of 10 mM. Drugs were from
Fisher and Sigma and were of the highest purity available.
The library was stored at −20 °C until use. Prior to use,
the library of drugs was thawed at room temperature.
Drugs of interest were isolated and reproduced from
prepared 10 mM solutions. Antimycin A, Captan, Chlor-
quinaldol, Clotrimazole, Disulfiram, Fluvastatin, Mycophe-
nolic Acid, Methylbenzethonium Chloride, Miconazole,
Nitroxoline, Octodrine, Pyrithione Zinc, Fluconazole, and
Octanoic Acid were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Nifuroxime was purchased from MP
Biochemicals (Solon, OH, USA). All drugs were prepared
to 10 mM using DMSO as the solvent. DMSO was pur-
chased from Amresco® (Solon, OH, USA). Fetal bovine
serum (Triple Membrane 0.1 μm filtered) was purchased
from GeneMate BioExpress (Kaysville, UT, USA).
Screening assay
The sensitivity of C. albicans to drugs was assessed by a
chemical screen. The absorbance at optical density at
600 nm (OD600) of yeast and bacterial overnight cultures
were determined for each of our experiments. The
absorbance values were then converted to cells/ml using
McFarland’s scale. Twenty five million Candida cells
were added to all 10 cm petri dishes; 600 million bacter-
ial cells were added to all 10 cm bacterial petri dishes.
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agar surface using a multichannel pipette and slight con-
tact of the tip to the agar made to leave an impression
to facilitate later analysis. Drugs that were replicated
were done on petri dishes, following the same protocol
in at least five independent experiments. For the replica-
tion studies, only a single drug was placed per plate. The
plates were incubated at either 25 or 37 °C for 24 h. The
drugs-of-interest were selected on their ability to pro-
duce a distinct zone of inhibition of fungal growth
greater than the zone made by DMSO alone and at the
same time that is comparable to, if not greater than the
positive control, Fluconazole. The zones of inhibition
were quantified by measuring their diameters in mm, as
recommended by the Clinical Laboratory Standards In-
stitute (CLSI) procedures outlined in the manual M44-
A2 [18, 19]. In addition, we utilized the software ImageJ
[20] to digitally quantify the magnitude of every zone of
inhibition.
E. coli and B. cereus were cultured overnight in liquid
LB media at 37 and 30 °C respectively. The sensitivity of
E. coli and B. cereus to Octodrine was assessed by spread-
ing 6 × 108 cells of their respective overnight cultures onto
petri dishes containing solid LB media. 5 μl of neat Octo-
drine was placed directly on the agar surfaces. The plates
with E. coli were incubated at 37 °C, while plates with
B. cereus were incubated at 30 °C for 24 h.
Determination of minimal effective drug concentrations
by drug diffusion susceptibility testing
Plates inoculated with C. albicans were prepared using
the protocol described above. To elucidate the ability of
the varying concentrations of drugs to form zones of in-
hibition, two-fold serial drug dilution experiments were
performed. To perform the first two-fold dilution, one
part of the 10 mM stock solution was mixed with one
part DMSO. Each subsequent dilution was done with al-
iquots from the prior dilution mixed with equal parts of
DMSO. 5 μl of each drug dilution was spotted onto a
lawn grown on YPD plate, as well as 5 μl of DMSO as a
negative control. Dilutions beyond 0.07813 mM that
were still forming a significant zone of inhibition were
further diluted on a separate plate. Drug-treated plates
were then incubated at either 25 or 37 °C for 24 h. Two-
fold serial dilutions of Octodrine were done on YPD and
Serum plates with undiluted Octodrine as the most con-
centrated solution.
Genotypic mutant screening against Octodrine
Each C. albicans knockout strain from one of the three C.
albicans libraries [15–17] was cultured in individual wells
of 96 well plate in 100 μl of YPD media overnight at 30 °C.
5 μl of each Candida knockout overnight culture was spot-
ted onto a YPD solid plate using a multichannel pipette.The cells were then left to absorb into the YPD plates for
1 h at 25 °C. Using a multichannel pipette, 5 μl of Octo-
drine 10 mM was spotted directly on top of the C. albicans
cells. The plates were then placed in an incubator set at
30 °C and left overnight. Analysis of plates consisted of iso-
lating any strains that exhibited resistance to 5 μl of
10 mM Octodrine. Resistance was noted by the ability of
the Candida cells and the subsequent drug-treated spot to
lack a zone of inhibition.
Mammalian cell culture, drug treatment, and survival
assay
RAW264.7 mouse macrophage cells (ATCC number TIB-
71) and human melanoma C32 cells (ATCC number
CRL-1585) were maintained in DMEM (Sigma-Aldrich)
supplemented with 10 % FBS (Bioexpress) and 100 μg/mL
penicillin and 100 μg/mL streptomycin. Mammalian cells
(10,000 per well) were seeded in 96-well plates (100 μl/
well) 24 h before the assay. During the assay, 1 μl of
10 mM drug was added to 100 μl of cell-containing media.
Two-fold serial dilutions of the media were performed.
RAW264.7 and C32 cells were treated with drugs for 24
and 48 h respectively, and determination of cell viability by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay was performed as described in [21]. Each
data point shown in the figure for MTT assays represents
the average of results from at least two wells in each of at
least two separate experiments. Cell viability is shown as
the percentage of survivors obtained relative to untreated
cells grown in media only (100 %).
Image capture and image processing
All images were taken with an 8MP iSight camera with
an aperture size of F2.4 and touch-to-focus capabilities.
Images were standardized with a universal template to
allow for direct comparison between images. Images are
stock and unaltered by any graphics editing software.
Results
Moderate ability of Fluconazole to kill serum-grown
Candida albicans at 37 °C
It has been reported that host serum markedly inhibits
growth of the human fungal pathogen, Candida albicans
[22–24]. We have confirmed these observations by
showing that Candida wild type strain SN250 [15] is un-
able to grow in liquid 100 % Fetal Bovine Serum at
either 25 or 37 °C (data not shown). However, during
the course of our experiments, we have observed that
Candida is able to grow and establish a lawn on solid
serum plates containing 62.5 % v/v FBS and 37.5 % v/v
agar solution, at both temperatures (Fig. 1a).
We investigated whether Fluconazole, the widely used
anti-Candida drug, was able to kill C. albicans on solid
serum plates. While Fluconazole was shown to be an
Fig. 1 The search for new antifungal drugs. a Analysis of C. albicans strain SN250 treated with various drugs. The strains were grown and exposed
to drugs determined to be drugs of interest by our chemical screen. The size of the zone of inhibition on each image is shown with the same
scale (mm), with standard deviation values are shown in Additional file 1: Table S1. Plates were treated with drugs after spreading of 200 μl of
liquid Candida culture and left to incubate overnight in either 25 or 37 °C. b The hits were classified into three classes: Antifungal, Antimicrobial,
and Miscellaneous drugs. Numbers within grey circles represent number of drugs of each class in JHCCL, while numbers in the transparent middle
circle shows the number of hits of drugs from our screen
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YPD plates, (Fig. 1a), we observed that Fluconazole
moderately inhibits the growth of Candida on serum
plates (Fig. 1a and Additional file 1: Table S1). It should
be noted, however that Fluconazole formed prominent
zone of inhibition on the solid YPD plates. In addition,
we observed that Fluconazole exhibited diminished ef-
fectiveness at forming zone of inhibition at 37 °C com-
pared to 25 °C (Fig. 1a and Additional file 1: Table S1).
We decided to assess the drug-pathogen interactions at25 °C in additional to body temperature because there is
a serious problem of Candida growth in catheters where
it may be exposed to serum at room temperatures [25].
Screening of inhibitors of Candida albicans lawn
formation
In light of the moderate effectiveness of Fluconzole to kill
C. albicans in serum at the physiologically relevant
temperature (37 °C), and in search for alternative anti-
fungal drugs, we decided to screen the library of chemicals
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to kill Candida albicans. JHCCL consists of 1581 FDA-
approved drugs, as well as drugs approved abroad, consist-
ing of small molecules (10 mM) that are used as treat-
ments for a variety of diseases, including, but not limited
to: infectious, neurodegenerative, psychiatric, cardiovascu-
lar diseases and cancer.
We identified inhibitors of Candida growth forma-
tion by performing a primary screen on the 1581 drugs
belonging to the JHCCL. We plated Candida on solid
YPD and serum plates, and placed 5 μl of each 10 mM
drug on top of the fungal lawn. We tested the effect of
exposure to each of the drugs from the library on their
ability to inhibit Candida growth, as well as their abil-
ity to form a zone of inhibition within the fungal lawn.
Based on this screen, we identified 15 drugs that
inhibit Candida growth on solely YPD or on both YPD
and serum plates in at least five independent experi-
ments at two temperatures, 25 °C and 37 °C (Fig. 1a).
We classified the 15 hits into three different classes to
facilitate interpretation of our results. They were: 6
hits from 32 known antifungals, 5 hits from 359 anti-
microbials/antiseptics, and 4 hits from 1190 other
multifunctional drugs (Fig. 1b). While these drugs were
chosen in these screens for their ability to inhibit C. albi-
cans lawn formation, the actual levels of inhibition varied
from weak to strong inhibition (Fig. 1a and Additional file
1: Table S1).
All 6 selected antifungal drugs, Antimycin A, Captan,
Clotrimazole, Fluconazole, Miconazole, and Pyrithione
Zinc showed strong inhibition of Candida growth on
YPD plates at 25 °C and 37 °C (Fig. 1a and Additional
file 1: Table S1). However, with the exception of the
pesticide Captan, all of the antifungals exhibited weak
inhibition of Candida growth on serum plates (Fig. 1a
and Additional file 1: Table S1).
Out of the five antimicrobial/antiseptic drugs selected
by our screen, Chlorquinaldol and Methyl-benzethonium
chloride displayed the strongest inhibition of C. albicans
growth on serum plates. Nifuroxime, Nitroxoline, and
Octanoic acid showed weaker inhibition of Candida
growth on serum plates (Fig. 1a and Additional file 1:
Table S1).
Interestingly, from a drug-repurposing point of view,
4 drugs from 1190 of the other multifunctional drugs,
showed anti-Candida activity on YPD plates (Fig. 1a
and Additional file 1: Table S1). Of those, Fluvastatin
and Mycophenolic acid showed very strong inhibition
of YPD grown Candida, but failed to inhibit its growth
on serum plates (Fig. 1a and Additional file 1: Table
S1). The other 2 drugs, Disulfiram and Octodrine
showed a consistent moderate-to-weak anti-Candida
activity on YPD and serum plates (Fig. 1a and
Additional file 1: Table S1).Diffusion susceptibility testing of the hits obtained from
the screen
The 15 hits from the primary screen consisting of antifun-
gals, antimicrobials, and miscellaneous drugs were tested
in diffusion susceptibility assays in order to determine
their potency against C. albicans lawns. These confirma-
tory screenings were performed over a range of drug
concentrations, where 5 μl of drugs within the range of
10 mM to 0.3 μM were applied on YPD-grown Candida
cells and plates were incubated for 24 h. YPD plates were
chosen as the testing media since some of the drug hits
were ineffective in inhibiting fungal growth on serum
plates. The efficacy of each drug was evaluated by estimat-
ing the inhibitory concentration at which the drug formed
a zone of inhibition on a fungal lawn of YPD plates.
We found that with the exception of Fluconazole and
Captan, all antifungals were able to inhibit Candida growth
in the μM drug range (Fig. 2 and Additional file 1: Table
S2). All five antimicrobial and antiseptic drugs were only
able to inhibit fungal growth in the mM drug concentra-
tions (Fig. 2 and Additional file 1: Table S2). Surprisingly,
among the drugs approved for non-infectious disease treat-
ments, Fluvastatin was able to inhibit C. albicans growth
in the μM drug concentration, while the rest of the drugs
were only inhibitory in the mM drug concentrations.
Broad-spectrum antimicrobial properties of Octodrine
Although nine antimicrobial and non-antimicrobial drugs
we discovered have not been approved by FDA to treat
fungal infections, eight of them were found previously to
kill Candida albicans [26–39]. Octodrine, the drug previ-
ously used as a decongestant [40, 41], showed an ability to
kill serum-grown C. albicans when applied at 10 mM 5 μl
drop (Fig. 1). Furthermore, Octodrine is the only drug that
has not been tested to kill fungi previously. We wanted to
investigate whether the application of an even higher con-
centration of Octodrine would augment its antifungal
properties. To test this, we applied 5 μl of neat, undiluted
Octodrine, which is produced in a liquid form, as well as
its two-fold serial dilutions on the serum and YPD grown
Candida lawn. We discovered that the undiluted amount
of Octodrine was effective in eliminating the fungal
growth (Figs. 3 and 4 and Additional file 1: Tables S3 and
S4). We also observed that Octodrine is more effective in
inhibiting serum grown Candida compared to YPD grown
Candida, as the inhibitory concentrations of Octodrine
were more pronounced on serum than on YPD plates
(Fig. 3, Additional file 1: Table S3).
In order to identify Candida proteins and signaling
pathways that mediate the lethality of Octodrine, we
screened three C. albicans knockout libraries, collect-
ively consisting of 908 mutant strains lacking one of the
previously demonstrated virulence genes, for any alter-
ations in sensitivity to 10 mM Octodrine. These libraries
0.30
0.24
Fig. 2 Agar drug diffusion susceptibility assay of Candida albicans SN250. Plates were treated with various concentrations of drugs after spreading
of 200 μl of liquid Candida culture and left to incubate overnight in either 25 or 37 °C. The middle of the plate served as the negative control,
DMSO. Dilutions that failed to exhibit discernable inhibition after one plates were further diluted a second time. The size of the zone of inhibition
on each image is shown with the same scale (mm), with standard deviation values are shown in Additional file 1 Table S2
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tial virulence genes [15], 96 cell wall protein mutants
[42], and 165 transcription factors mutants [43]. We
found that all Candida mutants were as sensitive to 5 μl
of 10 mM Octodrine as the wild type strain (Additional
file 1 Figure S1).
We hypothesized that Octodrine may kill microorgan-
isms by targeting their non-protein cellular components.
To investigate this we tested the sensitivities of Escherichia
coli strain C600 and Bacillus cereus strain 10987, gram-
negative and gram-positive bacteria, respectively, and
frequent disease-causing bacteria, to Octodrine. These
bacterial strains were chosen because they are wild type
strains with known genotypes and genomes [44, 45]. We
observed that 5 μl of neat Octodrine formed a prominent
zone of inhibition in both E. coli and B. cereus lawns (Fig. 4
and Additional file 1: Table S4), which suggests that Octo-
drine possesses wide spectrum antimicrobial properties.
Since Octodrine was one of the most prominent drugs
that killed C. albicans in serum, we tested the sensitivity
of mouse macrophage cell line RAW264.7 to Octodrine,
and compared it to the rest of selected drugs. Since
Octodrine stock was dissolved in DMSO, we had to test
the sensitivity of the cell line to this solvent alone. Cell
viability was determined by MTT assay (Methods) and
was calculated as the percentage of surviving cells in
various chemical concentrations relative to cells treated
with media alone. We observed that the sensitivity of
mouse macrophages to Octodrine was the close to the
sensitivity to the DMSO alone (Table 1). This strongly
suggests that Octodrine concentrations that kill Candidaalbicans in serum (Fig. 1a) do not affect the survival of
host phagocytes. The sensitivity of RAW264.7 cells to
DMSO has previously been reported [46], and is consist-
ent with the cellular sensitivity seen here. We tested the
sensitivity of RAW264.7 macrophage like cells because
macrophages are first line of defense against Candida,
and knowing the sensitivity of those cells to antifungal is
an important question. We confirmed these observations
by testing sensitivity of human skin melanoma cell line,
C32 (Table 1). With the exception of Octodrine, Floco-
nazole, Nifuroxime, and Fluvastatin, all other selected
drugs adversely affected the survival of host cells, which
suggests that they may have undesirable side effects
when used in blood. We chose this cell line because of
the relevance of skin to Candida infections.
Discussion
This study was designed to test FDA and foreign-approved
small molecules drugs for their antifungal properties, with
the objective of reducing the cost and time necessary to de-
velop much needed anti-Candida albicans therapies. This
library consists of an FDA-approved, off-patent collection
of 1581 small molecules (10 mM) that are used as drugs
for a variety of diseases, including infectious, neurodegen-
erative, psychiatric, cardiovascular diseases and cancer.
Such an approach would rapidly expedite the drug discov-
ery and development process since the general pharmacol-
ogy, toxicology, and pharmacokinetic properties of all
these drugs are already well established. This would facili-
tate the further analysis of the novel functionalities of the
established molecules because the structure, chemical
Serum
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3000 mM6000 mM (Neat) 1500 mM 750 mM 375 mM 187.50 mM
46.88 mM93.75 mM 23.44 mM 11.72 mM 5.86 mM 2.30 mM
7.10 1.41 0.44
Fig. 3 Agar Octodrine diffusion susceptibility assay of Candida albicans SN250. Plates were treated with various concentrations of Octodrine
after spreading of liquid Candida culture and left to incubate overnight in either 25 or 37 °C. The equal volume of negative control, DMSO,
was also included. The size of the zone of inhibition on each image is shown with the same scale (mm), with standard deviation values are
shown in Additional file 1 Table S3
Candida albicans Bacillus cereus Escherichia coli
32.99
10.865.64
Fig. 4 The sensitivities of Candida albicans, Escherichia coli, and Bacillus cereus to neat Octodrine. Plates were treated with 5 μl of undiluted Octodrine
after spreading of 200 μl of liquid Candida (25 × 106 cells) or bacterial cultures (600 × 106 cells) on 10 cm petri dish and left to incubate overnight in
either 37 °C for C. albicans and E. coli or in 30 °C for B. cereus. The size of the zone of inhibition on each image is shown with the same scale (mm),
with standard deviation values are shown in Additional file 1 Table S4
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Table 1 Minimal cytotoxic concentration (MCC) calculations for
the cell lines RAW264.7 and C32 treated with selected drugs








Methylbenzethonium Chloride 6.25 1.56
Miconazole 6.25 1.56
Mycophenolic Acid 0.78 1.56
Nifuroxime 25.00 25.00
Nitroxoline 6.25 6.25
Octanoic Acid 0.78 6.25
Octodrine 25.00 25.00
Pyrithione Zinc 0.78 1.56
DMSO 50.00 50.00
The solvent DMSO is used as a negative control. Mammalian cells were treated
with drugs at concentrations shown. The drugs were serially-diluted, and the
MCC is defined as the first concentration of the drug, which is able to lower
cell viability below 100 %. Cell viability was determined by MTT assay
(Methods) and is shown as the percentage of survivors relative to cells treated
with media alone
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of this library are known.
We have developed a serum-based assay to address the
limitations of currently used YPD media, whose compo-
nents do not represent in vivo components that support
the growth of Candida. The moderate-to-mild effective-
ness of Fluconazole and other FDA approved antifungal
drugs on our serum assay is comparable to the effective-
ness of Octodrine in killing serum-grown C. albicans.
In our study, fifteen out of 1581 drugs displayed anti-
Candida properties. Overall, all drugs discovered in our
study could be separated into three structural categories:
five-membered heterocyclic drugs, such as azoles and
oxoles, six-membered heterocyclic compounds (pyridines),
and other structures (Fig. 5). The fact that we selected six
drugs that were previously approved by FDA to treat fun-
gal infections biologically validates our approach. The six
antifungal drugs obtained as hits from the screen com-
prised three different chemical classes: azoles (Flucona-
zole, Captan, Clotrimazole, and Miconazole), pyridine
(Pyrithione Zinc), and other structures (Antimycin A).
Additionally, we found five antimicrobial/antiseptic drugs
to be effective at inhibiting C. albicans lawn formation in
the screen. These drugs include general antiseptics and
antibacterial antibiotics, and comprise three different
chemical classes: oxoles (Nifuroxime), pyridines (Nitroxo-
line and Chlorquinaldole), and other structures (Octanoicacid and Benzethonium Chloride) (Fig. 5). The fact that
these five other drugs that were approved by FDA to treat
other non-fungal infectious diseases were also observed to
kill Candida albicans shows that these drugs could be
repurposed to be broad-spectrum anti-microbial drugs.
Lastly, from the point of view of drug repurposing, the
most interesting class of drugs would be the one with
demonstrated activity against a variety of diseases, but
with no known or characterized antifungal activity to
date. From the screen, we found four drugs belonging to
this class to be effective in preventing Candida growth.
These drugs have been designed for several indications,
including immune-suppression (Mycophenolic acid), de-
terrent of alcohol consumption (Disulfiram), antihyperlipi-
demic (Fluvastatin), and decongestant (Octodrine). These
drugs comprise three different chemical classes: azole
(Fluvastatin), oxole (Mycophenolic acid), and other struc-
tures (Disulfiram and Octodrine) (Fig. 5). These four drugs
that were approved to treat non-infectious diseases showed
antifungal properties and thus, could be repurposed as
new antifungal drugs.
Recently, another group investigated the ability of FDA-
approved drugs to inhibit C. albicans biofilm formation
[12] by screening the Prestwick Library, a commercially
available chemical library of 1200 drugs. Interestingly, the
authors of that paper discovered several antifungal drugs
in common to our study: Miconazole, Clotrimazole, and
Methylbenzonium chloride. The difference between the
two studies is that Siles et al. [12] screened for drugs cap-
able of inhibiting Candida biofilm formation, while we
looked for FDA approved drugs capable of inhibiting the
growth of non-biofilm C. albicans growth. In addition,
with the exception of Octodrine, every one out of fifteen
discovered drugs in our study had been previously tested
for the ability to kill Candida albicans [26–39].
In this study, Octodrine, which was previously used as a
decongestant and registered under the name of Vaporpac
(Medley & James Laboratories) [40, 41], was a drug that
had not been previously established as an anti-fungal. We
observed that although its anti-Candida activity was mild
on YPD, it displayed one of the best Candida growth
inhibition on serum compared to other drugs. It also has a
potential to be one of the safest of the discovered drugs
because it did not affect the sensitivity of mammalian cells
significantly. The fact that no C. albicans mutants showed
a decrease in sensitivity to Octodrine argues against the
potential emergence of Octodrine-resistant Candida
strains, and favors the usage of this drug as a new antifun-
gal treatment against Candida. In addition, we showed
that Octodrine is capable of killing Gram-positive as well
as Gram-negative bacteria, making it a desirable broad-
spectrum antimicrobial countermeasure, that probably
kills microbes by targeting their non-protein components.
Octodrine was previously shown to agonize Estrogen
Fig. 5 Chemical structures of 15 drugs shown to have anti-Candida albicans activity in our screen. All drugs were categorized into 3 classes: 5-membered
heterocyclic (Azoles and Oxoles) and 6-membered heterocyclic (Pyridines) compounds, as well as drugs of other structures. The FDA approved applications
are shown in green. Substructures are indicated in red
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in vivo antimicrobial activity of Octodrine in humans
would have to be in the nM range to avoid this side effect.
As the pharmacokinetics of Octodrine had been previ-
ously established in numerous animal models [48], this ap-
proach is useful for the discovery of economically viable
new therapies against infectious diseases.
Conclusions
In summary, we have screened the Johns Hopkins Clinical
Compound Library, a commercially available chemical
library of FDA approved 1581 drugs, for the identification
of bioactive drugs against C. albicans growth. Our results
provide the comprehensive survey of the inhibition of
Candida growth by existing drugs, one of which hadn’t
been previously reported to have antifungal properties.
From a drug repurposing point of view, the identification
of drugs with no known antifungal activity and which
demonstrated excellent activity against C. albicans growth
in serum opens up a valuable new avenue for the rapid
development of antifungal agents, which are urgently
needed.
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